20 results about "He Antibody" patented technology

This disclosure provides an anti-5T4 antigen-binding domain that can be incorporated into antibodies and receptors, including a bispecific anti-5T4 antibody, a biparatopic anti-5T4 antibody, and its antibody-drug conjugate, comprising a first antigen-binding domain that specifically binds to a first 5T4 epitope, a second antibody-antigen-binding domain that specifically binds to a second 5T4 epitope that is not identical to the first 5T4 epitope (the first antigen-binding domain is operably linked to the second antigen-binding domain), and a chemotherapeutic agent. This disclosure further provides methods for using it for the treatment of cancer.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of an antibody two-dimensional code. The invention creatively develops a method for generating an antibody two-dimensional code (Ab-QRcode) only based on an antibody sequence without antigen information. The antibody two-dimensional code generated by the method can describe species specificity, variety and targeting specificity information of the antibody, and each antibody has a unique two-dimensional code which is unique and different from other antibodies. Based on the two-dimensional code, the target specificity of the antibody can be distinguished, and the antibody can be clustered according to the difference between the target specificity of the antibody, so that the clustering of the antibody for identifying the same or similar antigen can be realized.

The present invention specifically relates to a monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats and concatenates the MPXV A35S gene sequence via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

The present invention provides anti-human LILRB4 monoclonal antibodies or fragments thereof, immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, and methods for measuring human LILRB4.SOLUTION: Anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof that specifically bind to a human immunosuppressive receptor LILRB4 and inhibit binding between fibronectin and the human immunosuppressive receptor LILRB4, immune checkpoint inhibitors containing the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof as active ingredients, therapeutic agents for immune checkpoint-related diseases, and methods for measuring a human immunosuppressive receptor LILRB4 in a biological sample using the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof.SELECTED DRAWING: None

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

We provide camptothecin-based pharmaceuticals and their antibody conjugates. [Solution] A compound of the following formula I and its antibody complex are provided. JPEG2026086826000042.jpg62170 (In formula I, R1 and R2 are independently a C1-C3 alkyl group, -H, -CF3, aryl group, heteroaryl group, etc.)

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR58 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR58 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

This invention provides a series of antibodies or antigen-binding fragments thereof that have high specific binding ability to tumor cells expressing the ITGA2 protein. The antibodies or antigen-binding fragments of this invention can achieve excellent killing effects against tumor cells after being conjugated with a drug to form an antibody-drug conjugate.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.

The application discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR46 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR46 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody GR46 has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The present invention discloses camptothecin-class drugs and their antibody conjugates. Based on a comprehensive understanding of ADC-class drugs, the inventors have designed a series of active derivatives of antitumor camptothecin. The designed antitumor molecular compounds have shown good antitumor activity in experiments.

The application discloses an inhibitory antibody or antigen-binding fragment thereof against human OX40, a preparation method and application, and belongs to the technical field of biological immunity. The human-mouse chimeric antibody Y07-L2 and the humanized antibody Y07-C2 prepared by the application have similar EC50 in combination with human OX40, and are similar to the targeted antibody drug KHK-4083 in inhibiting OX40. The heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is shown as SEQ ID NO. 14, and the light chain variable region is shown as SEQ ID NO. 15; the heavy chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 20, and the light chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 21; the CDR region of the humanized antibody Y07-C2 is subjected to mutation, and the mutant antibody Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR39 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR39 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR39 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR39 has high affinity and dilution stability and is suitable for clinical large-dose administration.

This invention discloses an anti-ROR1 antibody or its antigen-binding fragment, relating to the fields of biotechnology and medical technology. Ten antibodies with high affinity for the ROR1 protein were screened and can specifically bind to it. This allows for the development of ROR1 detection kits, tumor diagnostic and prognostic kits, as well as antibody-containing pharmaceutical compositions, antibody-drug conjugates, and other antibody-based therapeutic methods. Experimental verification shows that the antibodies provided by this invention have a high killing rate against tumor cells. All of the above antibodies exhibit antibody concentration-dependent cytotoxicity (ADCC), with higher antibody concentrations resulting in better anti-tumor activity. Therefore, the antibodies or their antigen-binding fragments provided by this invention show promising potential for the preparation of tumor therapeutic drugs.

The present invention specifically relates to a monoclonal antibody 8D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats the MPXV A35S gene sequence in tandem via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 8D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR75 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR75 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR12 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR12 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The invention provides a blocking type GIPR antibody, an antigen binding fragment thereof, an antibody conjugate and application of the antibody conjugate in preparation of drugs. The GIPR antibody and the antigen binding fragment thereof have relatively high affinity to GIPR protein, and are combined with the GIPR protein expressed on the surface of a cell to block the activity of the GIP activated cell; the GIPR antibody has relatively good cell internalization activity, pharmacokinetic studies show that the GIPR antibody and the antigen binding fragment thereof show relatively good stability in a mouse body, and AUC0-t can be up to 15033.01 hou * [mu] g / mL at most. An antibody conjugate prepared from the GIPR antibody shows the activity of stably and lastingly reducing the weight of an experimental animal model, and has a wide application prospect.

This invention discloses a novel coronavirus neutralizing antibody, a detection kit, and their applications. The amino acid sequence of the variable region of the heavy chain of the neutralizing antibody is shown in SEQ ID No. 1, and the amino acid sequence of the variable region of the light chain is shown in SEQ ID No. 2. This invention optimizes the antibody screening process by screening antibodies with mature affinity through bioinformatics analysis of single B cells, combined with single-cell RNA sequencing, VDJ rearrangement analysis, and somatic hypermutation studies, avoiding the blindness of traditional methods and improving the accuracy and effectiveness of antibody screening. The neutralizing antibody GR39 provided by this invention has variable regions of both its heavy and light chains that specifically bind to the RBD domain of SARS-CoV-2 and the S-Trimer domain of the Omicron variant, achieving broad-spectrum neutralization of SARS-CoV-2 virus and its variants. The binding activity of antibody GR39 to S-Trimer and RBD at 2-fold and 300-fold dilutions is significantly superior to other antibodies, indicating its high affinity and dilution stability, making it suitable for high-dose clinical administration.